Xifaxan patent loss causes Bausch shares to tumble
The invalidation of US rights underpinning the anti-intestinal-infection drug has shaken confidence in the company’s future
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.